Literature DB >> 18271926

Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition.

Ahmed S Sultan1, Hassan Brim, Zaki A Sherif.   

Abstract

Signal transducer and activator of transcription (Stat) 5 appears to play a vital role in prolactin (PRL)-induced cell differentiation and normal mammary gland development. We previously showed that PRL-activated Stat5a induced expression of E-cadherin-beta-catenin complex in vitro and in xenotransplant tumors in vivo led to inhibition of breast cancer invasion. In the present study, we show that human breast cancer cells co-overexpressing Stat5a and its tyrosine kinase (Jak) 2 cultured in three-dimensional (3D) Matrigel culture demonstrate changes consistent with induction of mesenchymal-epithelial redifferentiation. Jak2 and Stat5a-co-overexpressing cells treated with cocktail (PRL, dexamethasone, and insulin), effectively reverse epithelial-mesenchymal transition by stimulating 3D organoids more reminiscent of the acinar growth of normal mammary epithelial cells, compared with cells overexpressing only Stat5a or Jak2. In contrast, dominant-negative dominant-negative-Stat5 blocks 3D organoid formation, causing cells to grow in layers instead. Hyperactivation of Jak2 and Stat5a in T-47D cells induces alveolar-like structures, mamospheres, with marked lumen formation through central apoptosis and restores a polarized epithelial phenotype. However, Jak2 and Stat5a overexpression in BT-20 cells induces partially differentiated 3D organoids with no central lumen, but effectively re-expresses estrogen receptor alpha. Jak2 and Stat5a-induced 3D differentiated organoids are accompanied by increased expression of E-cadherin, zonula occludens-1, and cytokeratins 8 and 18, and decreased levels of vimentin and Snail, indicating a shift from a mesenchymal phenotype toward an epithelial phenotype. Collectively, Jak2 and Stat5a co-overexpression cooperatively reverses epithelial-mesenchymal transition and promotes differentiation in human breast cancer cells, which may provide a mechanism to explain the invasive suppressor role of PRL-activated Stat5a in mammary cancer cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18271926     DOI: 10.1111/j.1349-7006.2007.00685.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  29 in total

1.  Conditional knockout of fibronectin abrogates mouse mammary gland lobuloalveolar differentiation.

Authors:  Keyi Liu; Le Cheng; Andrea Flesken-Nikitin; Lynn Huang; Alexander Y Nikitin; Bendicht U Pauli
Journal:  Dev Biol       Date:  2010-08-10       Impact factor: 3.582

2.  Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

Authors:  Amy R Peck; Agnieszka K Witkiewicz; Chengbao Liu; Ginger A Stringer; Alexander C Klimowicz; Edward Pequignot; Boris Freydin; Thai H Tran; Ning Yang; Anne L Rosenberg; Jeffrey A Hooke; Albert J Kovatich; Marja T Nevalainen; Craig D Shriver; Terry Hyslop; Guido Sauter; David L Rimm; Anthony M Magliocco; Hallgeir Rui
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

3.  Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis.

Authors:  Anne M Miermont; Angela R Parrish; Priscilla A Furth
Journal:  Carcinogenesis       Date:  2010-02-24       Impact factor: 4.944

4.  Matrix compositions and the development of breast acini and ducts in 3D cultures.

Authors:  Muthulekha Swamydas; Jill M Eddy; Karen J L Burg; Didier Dréau
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-06-29       Impact factor: 2.416

5.  Signal transducer and activator of transcription-3 and breast cancer prognosis.

Authors:  Takahiro Sato; Lynn Moretti Neilson; Amy R Peck; Chengbao Liu; Thai H Tran; Agnes Witkiewicz; Terry Hyslop; Marja T Nevalainen; Guido Sauter; Hallgeir Rui
Journal:  Am J Cancer Res       Date:  2011       Impact factor: 6.166

6.  PTP1B suppresses prolactin activation of Stat5 in breast cancer cells.

Authors:  Kevin J Johnson; Amy R Peck; Chengbao Liu; Thai H Tran; Fransiscus E Utama; Ashley B Sjolund; John D Schaber; Agnieszka K Witkiewicz; Hallgeir Rui
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

7.  Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.

Authors:  Thai H Tran; Fransiscus E Utama; Justin Lin; Ning Yang; Ashley B Sjolund; Amy Ryder; Kevin J Johnson; Lynn M Neilson; Chengbao Liu; Kristin L Brill; Anne L Rosenberg; Agnieszka K Witkiewicz; Hallgeir Rui
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

8.  Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas.

Authors:  Erika Michel; Stefanie K Feldmann; Mariusz P Kowalewski; Carla Rohrer Bley; Alois Boos; Franco Guscetti; Iris M Reichler
Journal:  BMC Vet Res       Date:  2012-05-30       Impact factor: 2.741

9.  Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.

Authors:  T M Ward; E Iorns; X Liu; N Hoe; P Kim; S Singh; S Dean; A-M Jegg; M Gallas; C Rodriguez; M Lippman; R Landgraf; M D Pegram
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

10.  Global profiling of prolactin-modulated transcripts in breast cancer in vivo.

Authors:  Takahiro Sato; Thai H Tran; Amy R Peck; Chengbao Liu; Adam Ertel; Justin Lin; Lynn M Neilson; Hallgeir Rui
Journal:  Mol Cancer       Date:  2013-06-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.